Sapient Capital LLC Invests $1.63 Million in Pfizer Inc. (NYSE:PFE)

Sapient Capital LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, Holdings Channel reports. The fund acquired 56,603 shares of the biopharmaceutical company’s stock, valued at approximately $1,630,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Briaud Financial Planning Inc acquired a new position in Pfizer in the third quarter valued at $30,000. Mizuho Securities Co. Ltd. purchased a new stake in Pfizer in the 3rd quarter valued at about $34,000. VisionPoint Advisory Group LLC increased its stake in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC lifted its holdings in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new stake in Pfizer in the fourth quarter valued at approximately $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.4 %

PFE stock traded up $0.11 during mid-day trading on Friday, hitting $27.81. 60,568,852 shares of the company were exchanged, compared to its average volume of 41,900,304. The firm has a fifty day simple moving average of $26.88 and a 200 day simple moving average of $28.21. The company has a market capitalization of $157.48 billion, a PE ratio of -463.42, a price-to-earnings-growth ratio of 1.18 and a beta of 0.63. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the prior year, the firm posted $1.23 earnings per share. Pfizer’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.36 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.04%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $36.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.